LOS ANGELES, CA / ACCESSWIRE / May 30, 2019 / Compare-autoinsurance.org has released a new blog post that explains how to compare car insurance quotes online and find affordable coverage.

Now it easier to get quotes, when compared with the old days, when drivers had to talk to an agent. Online car insurance quotes are easy and fast to obtain. Websites like http://compare-autoinsurance.org/ allow customers to get multiple quotes at once and discover the best rates in the area.

The best online price comparison tool. Online quotes are provided by either insurance companies or brokerage websites which cooperate with insurers. Either way, it is important to get as many quotes as possible.

Make sure to get quotes for the same coverage. Do not compare prices for different products. For example, the price for collision will be totally different from the one for comprehensive because different factors are analyzed. Also, make sure that the quoted products also include the same extra services, deductibles and discounts.

Gather a sufficient number of quotes before comparing. Make sure to gather a sufficient number of quotes for a fair comparison. If the quotes are for the same product and are accurate, the prices should not differ a lot. It is recommended to get at least 5-10 quotes.

There are two ways to get quotes: from an insurer or from a brokerage website.

If a person gets quotes directly from providers, it would take them about 5-10 minutes to fill in a form and wait for answers. We are talking about extended forms, not submit forms with 3-4 questions. For ten quotes, it may take that person almost two hours. This is why most people usually stop at 5 quotes using this method.

However, the alternative will provide a high number of quotes in the shortest time available. Using brokerage websites will help to get 5-10 quotes on a single page, with a single search run. After getting a reasonable number of quotes, at least 5, then the customer should start comparing policies. Always make a top of the highest rated companies and try to get quotes from them.

“Comparing car insurance quotes online will help you get the best coverage on the market”, said Russell Rabichev,
Marketing Director of Internet Marketing Company.

Compare-autoinsurance.org is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc.

For more information, please visit http://compare-autoinsurance.org/

Contact: cgurgu@internetmarketingcompany.biz

SOURCE: Internet Marketing Compan

ReleaseID: 547115

LOS ANGELES, CA / ACCESSWIRE / May 30, 2019 / Crescita Therapeutics Inc. (TSX: CTX and OTC Pink: CRRTF) (Crescita or the Company), a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, announced today that its Executive Chairman, Dan Chicoine will be presenting at the 9th annual LD Micro Invitational on Tuesday, June 4th at 3:00 p.m. pacific time. Mr. Chicoine accompanied by Ms. Linda Kisa, Crescita’s director of investor relations, will also be meeting with investors one-on-one.

“We are very excited to be presenting at this prestigious conference and we look forward to introducing Crescita to a new list of potential U.S. investors” stated Dan Chicoine, executive chairman.

The LD Micro Invitational will take place June 4th and 5th in Los Angeles, at the Luxe Sunset Bel Air Hotel, will feature 230 companies, and will be attended by over 1,000 individuals.

Please visit https://www.ldmicro.com/profile/CTX.TO to view Crescita Therapeutics’ profile.

Profiles powered by LD Micro – News Compliments of Accesswire

About Crescita Therapeutics Inc.

Crescita (TSX: CTX and OTC Pink: CRRTF) is a publicly traded, Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions and diseases and their symptoms. Crescita owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active drugs into or through the skin. Please visit www.crescitatherapeutics.com for additional information.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit, and Main Event). In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD Micro will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe.

For further information:

Investor Relations
Email: ir@crescitatx.com

Or

Glen Akselrod
905-326-1888 extension 10
glen@bristolir.com
www.bristolir.com

SOURCE: Crescita Therapeutics Inc

ReleaseID: 547099

PHOENIX, AZ / ACCESSWIRE / May 30, 2019 / The Stock Day Podcast welcomed TerraX Minerals Inc. (OTC PINK: TRXXF), a junior gold exploration company focused on creating shareholder value through discovery. President and CEO, David Suda, joined Stock Day host Everett Jolly.

Jolly began the interview by asking Suda what makes the Company, as well as the gold industry, special. Suda explained that several factors of the current economy are adding value to the gold industry, making it an excellent time to invest in this space. One of the biggest challenges facing this industry is the discovery of sites with large gold deposits, which is an area the Company specializes in.

“It’s our thesis that the mergers and acquisitions that you see going on are not going to fix the real problem, which is really just a lack of major gold discovery. By simple supply and demand, the lack of supply will support higher gold prices,” explained Suda.

He further explained that the Company’s flagship project is a 783 sq km area located in the City of Yellowknife in the Northwest Territories, which represents an area with great potential and value.

Jolly then asked how the Company’s Yellowknife City Gold project is progressing. Suda shared that after gathering substantial data on the area, the Company is preparing to drill this summer. Drilling will vary in depth and location throughout the project in order to best diversify their search.

Suda then explained that the Company has been focusing the majority of their efforts on high potential drill targets for this summer. He added that the Company also plans to continue to define the extension of the Giant Mine, which is adjacent to one of the Company’s targets and produced substantial deposits in previous years.

To close the interview, Suda shared that the Company’s current project has an incredible level of potential and added that now is one of the best times to invest in the gold industry.

To hear David Suda’s entire interview, follow the link to the podcast here:

https://audioboom.com/posts/7274839-ceo-david-suda-of-terrax-minerals-inc-otcpink-trxxf

Investors Hangout is a proud sponsor of “Stock Day,” and encourages listeners to visit the company’s message board at https://investorshangout.com/

About the Yellowknife
City Gold Project

The Yellowknife City Gold (“YCG”) project encompasses 783 sq km of contiguous land immediately north, south and east of the City of Yellowknife in the Northwest Territories. Through a series of acquisitions, TerraX controls one of the six major high-grade gold camps in Canada. Being within 10 km of the City of Yellowknife, the YCG is close to vital infrastructure, including all-season roads, air transportation, service providers, hydro-electric power and skilled tradespeople.

The YCG lies on the prolific Yellowknife greenstone belt, covering 70 km of strike length along the main mineralized break in the Yellowknife gold district, including the southern and northern extensions of the shear system that hosted the high-grade Con and Giant gold mines. The project area contains multiple shears that are the recognized hosts for gold deposits in the Yellowknife gold district, with innumerable gold showings and recent high-grade drill results that serve to indicate the project’s potential as a world-class gold district.

For more information on the YCG project, please visit our web site at www.terraxminerals.com.

On behalf of the Board of Directors

“DAVID SUDA”
David Suda
President and CEO

For more information,
please contact:

Samuel Vella
Manager of Corporate Communications
Phone: 604-689-1749
Toll-Free: 1-855-737-2684
svella@terraxminerals.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors – including the availability of funds, the results of financing efforts, the completion of due diligence and the results of exploration activities – that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, events or otherwise.

About The “Stock Day”
Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.

SOURCE CONTACT:

Stock Day Podcast
602-821-1143

SOURCE: Stock Day

ReleaseID: 547064

DOUGLAS, ISLE OF MAN / ACCESSWIRE / May 30, 2019 / Equiom, the global professional services provider, has announced its partnership with leading global alternative investment firm, Värde Partners. Värde has invested in Equiom as a long-term equity partner to help fund future expansion in line with the company’s growth strategy. Värde joins Equiom’s longstanding equity partner LDC, which has supported Equiom’s growth since investing in the business in 2013.

Sheila Dean, Global CEO, Equiom

Värde manages $14 billion in assets and invests across a broad array of geographies and strategies, including more than 20 years of experience investing in the financial services sector.

Equiom’s Global CEO, Sheila Dean, says the addition of Värde will help support the company’s future goal of diversification and expansion into new markets: “We are excited to begin a relationship with our new equity partner, Värde. Equiom has grown considerably since securing its first equity partner in 2006, completing 24 acquisitions and now with an established presence in Europe, the Middle East, Asia and the Americas. With plans for further expansion and diversification of our service lines, we require additional backing to achieve our goals. I’m personally very grateful for the strategic input and support we get from our equity partners, banking partners, corporate advisors Deloitte and legal advisors Gowling WLG, as it is crucial to strengthening the business with our ultimate aim of providing the highest level of professional service to new and existing clients worldwide. I’d particularly like to thank our banking partners RBS, Santander, Lloyds, M&G, Hermes and Investec for their support to date and I’m delighted to welcome KKR and Alcentra to that group. I’m also naturally very happy that LDC is staying on as an equity partner – it’s a strong endorsement of their belief in our business and confidence in Equiom’s future success.”

Elena Lieskovska, Partner and Head of European Financial Services at Värde

Elena Lieskovska, Partner and Head of European Financial Services at Värde, added: “We are excited to partner with Equiom and support the growth of the business. With a rich history and ambitious plans for expansion, we believe Equiom is positioned for continued success. This transaction supports our objective to create value by building long-term partnerships in the financial services industry. Värde was represented by international law firm Proskauer Rose LLP, who Värde engaged on M&A, Funding, and Structuring workstreams.”

Yann Souillard, Head of London at LDC said: “It has been very rewarding to see the success and growth of Equiom since we started our relationship with Sheila and the team in 2013, and we’re very much looking forward to continuing our relationship and that success alongside our colleagues at Värde.”

For more information visit equiomgroup.com/about-equiom/the-equiom-way

Notes to editor

About Equiom

Equiom is a global professional services provider, working with private, corporate and institutional clients to navigate twists and turns to achieve their ambitions. Equiom provides an unrivalled breadth of bespoke end-to-end wealth protection and support services to private clients, corporate clients and funds to facilitate wealth generation and security. It delivers those services “The Equiom Way” – with passion, reliability and responsiveness.

For information on the regulatory status of our companies, please visit equiomgroup.com/regulatory

About Värde Partners

Värde Partners is a $14 billion global alternative investment firm that employs a value-based approach to investing across a broad array of geographies, segments and asset types, including corporate credit, financial services, real estate, mortgages, energy, real assets and infrastructure. The firm sponsors and manages a family of private investment funds with a global investor base that includes foundations and endowments, pension plans, insurance companies, other institutional investors and private clients. Now in its third decade, Värde employs more than 300 people globally with regional headquarters in Minneapolis, London and Singapore.

For more information about Värde Partners, visit: www.varde.com.

About LDC

LDC, the private equity arm of Lloyds Banking Group, backs ambitious management teams from UK-based medium sized companies that are seeking up to £100million of investment to fund management buyouts or development capital transactions.

The firm invests in a broad range of sectors and has a portfolio of 90 businesses across the UK which collectively generates £5billion of revenues and employs in excess of 32,000 people.

For more information about LDC, visit: www.ldc.co.uk.

Media contacts:

Equiom: carolineashley@equiomgroup.com

+ 44 1624 699117

Sophie Millward on behalf of LDC: sophie.millward@citypress.co.uk

+44 (0)161 235 0350 / +44 (0)7890 616 295

Värde Partners: communications@varde.com

SOURCE: Equiom

ReleaseID: 546987

TORONTO, ON / ACCESSWIRE / May 30, 2019 / Kontrol Energy Corp. (CSE: KNR, OTCQB: KNRLF, FSE:1K8) (“Kontrol” or ‘Company’) a leader in the energy efficiency sector through IoT, Cloud and SaaS technology announces its financial results for the fiscal quarter ended March 31, 2019.

A complete set of Financial Statements and Management’s Discussion & Analysis will be filed on SEDAR (www.sedar.com) on May 30th at 4:30pm (EST). A conference call to discuss the Q1 2019 financial results has been scheduled for May 30th at 4:30pm (EST). See details below.

Highlights

Revenue for the three months ended March 31, 2019 was $3.7 million, up 67% over the prior year

Adjusted EBITDA for three months ended March 31, 2019 was $267,796

Cash flows from operating activities for the three months ended March 31, 2019 was $353,883

Kontrol Energy’s operating subsidiary ORTECH Consulting Inc. receives $565,000 order from Global Cement Company

Kontrol Energy and Toyota Tsusho Canada Inc. commenced initial deployment of IoT enabled energy monitoring and analysis over a select number of Smart Factory sites

Completed purchase of patents, intellectual property and computer equipment from DIMAX Controls Canada Inc. and rebranded as SmartSite®

Commenced due diligence process in connection with signed Letter of Intent to acquire 100% of the shares of an electrical efficiency company

Private placement funding and exchange of debentures; holders of up to $5,245,000 can exchange their 2019 debentures for 2020 debentures bearing interest at 8% per annum

Initiated application for DTC trading Eligibility of Kontrol Energy shares on the U.S. OTCB Market

Management Commentary and Q1 2019 Financial Highlights

“We had strong start to 2019 with revenue, EBITDA, and cash flow all higher compared to the first quarter of the prior year”, said Paul Ghezzi, CEO of Kontrol Energy. “Cash flows from operating activities improved by over $1.1 million in Q1 2019 compared to Q1 2018. The Company’s organic growth expectations are on track and we continue to execute on our acquisition strategy.”

Three months ended

Financial Results

March 31, 2019

March 31, 2018

Revenue

$3,678,360

$2,196,564

Gross profit

$1,860,260

$1,282,435

Net loss

$(681,196)

$(1,000,935)

Basic and Diluted EPS

$(0.03)

$(0.04)

Add for adjusted EBITDA reconciliation:

Amortization and depreciation

$459,424

$266,688

Finance expense

$229,510

$120,728

Share based compensation

$254,180

$170,400

Acquisition related expenses

$5,878

$0

Adjusted EBITDA*

$267,796

$(443,119)

Cash flows from (used in) operating activities

$353,883

$(821,613)

Gross profit for the three months ended March 31, 2019 was $1,860,260 an increase of $577,825 over the comparative quarter of the prior year. First quarter gross profit reflects strong contributions from SaaS, instrumentation sales, energy retrofit activities, audit and design services, and continuous emission installations.

Adjusted EBITDA for the three months ended March 31, 2019 was $267,796 compared to negative $(443,119) for the first quarter of the prior year. The improvement in earnings in the first quarter reflects new business activities coming online from the completed 2018 acquisitions along with organic growth. The impact of accretive acquisitions and overall scaling of operations has resulted in significantly lower operating expenses as a percentage of revenue. With growing revenues, overhead expenses are spread over a much larger operational base.

Cash flows from operating activities was $353,883 for the three months ended March 31, 2019. While cash flows used in operating activities was $821,613 for the three months ended March 31, 2018. This is a significant positive change of $1,175,496 and reflects strong working capital management and improved operational performance.

As Kontrol continues to execute on its growth plans, the Company is taking a systematic approach to rationalizing operating expenses across completed acquisitions and the Company is benefiting from a successful action plan to generate revenue synergies across verticals.

* Adjusted EBITDA is a non-IRFS financial measure. The Company defines Adjusted EBITDA as net income or loss before interest, income taxes, amortization and depreciation, share based compensation, and acquisition related expenses.

Conference call details

Join the meeting at: join.me/940-901-692. Select the preferred audio mode when prompted. Dial in by phone options can be selected under audio mode. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the conference call. The conference call will be archived at https://www.kontrolenergy.com/investors for one year.

About Kontrol Energy

Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.

Kontrol Energy was recently announced as the 7th fastest growing Startup in Canada by Canadian Business and Maclean’s.

Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com

For further information, contact us at admin@kontrolenergy.com Kontrol Energy Corp., 180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8 Tel: 905.766.0400, Toll free: 1.844.566.8123

For further information, contact:

Paul Ghezzi, Chief Executive Officer
paul@kontrolenergy.com
Kontrol Energy Corp.,
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information

Certain information included in this press release, including information relating to future financial or operating performance and other statements that express the expectations of management or estimates of future performance constitute “forward-looking statements”. Such forward-looking statements include, without limitation, statements regarding possible future acquisitions and/or investments in operating businesses and/or technologies, accelerated organic growth, Adjusted EBITDA, expansion of smart energy technologies into US markets, strategic partnerships to expand into North American Markets, acceleration of recurring SaaS revenues, the provision of solutions to customers and Greenhouse Gas emissions reductions, proposed financial savings and sustainable energy benefits and energy monitoring. Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief are based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that suitable businesses and technologies for acquisition and/or investment will be available, that such acquisitions and or investment transactions will be concluded, that sufficient capital will be available to the Company, that technology will be as effective as anticipated, that organic growth will occur, and others. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Such risks include, but are not limited to, lack of acquisition and investment opportunities or that such opportunities may not be concluded on reasonable terms, or at all, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and the Company does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise, except as required under applicable securities law.

SOURCE: Kontrol Energy Corp.

ReleaseID: 547093

COLUMBIA, SC / ACCESSWIRE / May 30, 2019 / Smith-Midland Corporation (OTCQX: SMID) division announcement.

Smith-Midland’s South Carolina division, Smith-Columbia, has been contracted to manufacture a 37 Easi-Set Building order by Atlanta based contractor Reams Enterprises. The GSA contract for U.S. Army base Fort Benning will include: (7) 26’x22′ multi-user men’s and women’s plumbed latrines; (13) 80’x20′ classrooms; (13) single unit 12’x10′ ammo buildings; (3) double unit 24’x10′ ammo buildings; and (1) 14’x8′ grenade bunker.

Fort Benning straddles the Georgia and Alabama lines across the Chattahoochee River just south of Columbus, GA. The base supports more than 120,000 active-duty military, family members, reserve component soldiers, retirees, and civilian employees, and includes the headquarters of the U.S. Army Rangers.

The contract awarded to Reams Enterprises is for upgrades to the Malone Ranges, a massive arms training complex that is also home of the annual “Best Ranger Competition,” held to determine the best two-man team from the entire United States Armed Forces. The subcontract value to Smith-Columbia will amount to $2.4 million, which includes delivery and installation.

Over 350 precast concrete Easi-Set Building panels are being engineered by Smith-Midland and manufactured by Smith-Columbia. A quick 90-day turnaround has been required, with project completion scheduled for mid-summer.

Discover more about Easi-Set Buildings at www.easisetbuildings.com.

About Smith-Columbia

Smith-Columbia is the South Carolina division of the Smith-Midland Corporation, a publicly traded company (OTCQX: SMID). Smith-Midland develops, manufactures, and sells a broad array of precast concrete products for use primarily in the construction, transportation, and utilities industries. Smith-Midland Corporation has three manufacturing facilities located in Midland, Va., Reidsville, N.C., and Columbia, S.C. For more information, please call (540) 439-3266 or visit www.SmithColumbia.com or www.SmithMidland.com.

Sales Inquiries: info@smithcolumbia.com
(803) 708-2222

Forward-Looking Statements

This announcement contains forward-looking statements, which involve risks and uncertainties. The Company’s actual results may differ significantly from the results discussed in the forward-looking statements. Factors which might cause such a difference include, but are not limited to, product demand, the impact of competitive products and pricing, capacity and supply constraints or difficulties, general business and economic conditions, out debt exposure, the effect of the Company’s accounting policies and other risks detailed in the Company’s Annual Report on Form 10-K and other filings with the Securities and Exchange Commission.

For more complete information on Smith-Midland Corporation, visit the Company’s web site at SMITHMIDLAND.com. The ”Investor Relations” area will include the Company’s Form 10-K.

SOURCE: Smith-Midland Corporation

ReleaseID: 547024

BOSTON, MA / ACCESSWIRE / May 30, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer and other diseases, announced today that Stephen Yoder, President and Chief Executive Officer of Pieris Pharmaceuticals, Inc., will present at the Jefferies 2019 Healthcare Conference in New York, New York on Thursday, June 6, 2019 at 3:30 PM (EDT). A webcast of the company’s presentation will be available at this link.

About Pieris Pharmaceuticals

Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes inhalable Anticalin proteins to treat respiratory diseases, immuno-oncology multi-specifics tailored for the tumor microenvironment, and a half-life-optimized Anticalin protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin® is a registered trademark of Pieris. For more information, visit www.pieris.com.

Forward Looking Statement

This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the expected timing of the filing of our Annual Report on Form 10-K including our audited financials, references to novel technologies and methods and our business and product development plans, including the advancement of our proprietary and co-development programs into and through the clinic and the expected timing for reporting data or making IND filings related to our programs, and partnering prospects for any such programs. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates, including our ability to recruit and enroll patients in our studies; our ability to address the requests of the FDA; competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC available at www.sec.gov, including without limitation the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and the Company’s Quarterly Reports on Form 10-Q.

Company Contact:

Pieris Pharmaceuticals, Inc.
Dr. Allan Reine
SVP & Chief Financial Officer
+1 857 246 8998
reine@pieris.com

Investor Relations Contact:

Pieris Pharmaceuticals, Inc.
Maria Kelman
Director of Investor Relations
+1 857 362 9635
kelman@pieris.com

SOURCE: Pieris Pharmaceuticals, Inc.

ReleaseID: 546978

Funding Would Support Emerging Medical Waste Treatment Application

PHOENIX, AZ / ACCESSWIRE / May 30, 2019 / Taronis Technologies, Inc., (“Taronis” or “the Company”) (NASDAQ: TRNX), a leading clean technology company in the renewable resources and environmental conservation industry, today announced the submission of a €3.0 million grant application under the European Commission’s Horizon 2020 grant funding program. The proposal was titled: “Sterilimed: Removal of Toxic Compounds and Sterilization of Hospital Compounds and Sterilization of Hospital Wastewater and Medical Waste Using Plasma Technology.”

The purpose of this grant is to gather the critical efficacy data and demonstrate the commercial viability of an emerging need in the hospital industry across the European Union. In March 2019, the European Commission launched its Strategic Approach to Pharmaceuticals in the Environment. One of the significant end results of this study may be critical changes in the regulation of hospital and medical wastes releases into the environment.

Under its Ireland-based subsidiary, Taronis has partnered with three leading research organizations to complete the grant submission. The organizations are as follows: CEW of the Netherlands, SINTEF from Norway, and HM Hospitales from Spain, who all joined and contributed greatly to the project and the grant application process. Each of these organizations is expected to play a critical role in the project if it is approved and funded. The application process is expected to take approximately six months, and the project would begin in early 2020 if approved.

“The research and data that could be generated by this project could prove to be extremely valuable,” commented Scott Mahoney, CEO of Taronis. “To date, we have proven that our patented plasma arc technology has the ability to sterilize a variety of waste streams, effectively killing all living organisms. We have also demonstrated that we could break down complex compounds such as cyanobacteria toxins and pharmaceuticals.”

“We believe this emerging hospital waste treatment opportunity could develop into a third meaningful commercial application in a highly scalable end market for our water decontamination technology. We are grateful for the support of CEW, SINTEF, HM Hospitales and Ernst and Young for their contributions to the application process. We are confident that the project would successful if approved and funded,” concluded Mr. Mahoney.

About CEW

The Centre of Expertise Water Technology (CEW) is headquartered in Leeuwarden, and is the leading knowledge and innovation centre in the Netherlands for applied research and product development in the field of water technology. The CEW brings together expertise from education, research, government and industry. Students, professors and other professionals conduct research together with, or on behalf of companies, in advanced 34 laboratories, application centres and at various pilot and demo sites. CEW counts 8 permanent staff and a turnover of EUR 1.9m.

As a public private partnership between knowledge and research institutions, institutions for vocational education (Higher Education), governmental organisations and entrepreneurs, it develops knowledge of talent for the international water sector and shortens the valorisation process for the innovative industry. CEW works together with students and knowledge workers on applied research and product development. In this way, CEW trains future staff for the high-profile water sector. Research topics include saving and reusing water, water and energy, nutrients and agriculture, the water system, industrial water as well as sensor technologies.

About SINTEF

SINTEF Energi AS (SINTEF-ER) is part a legal entity within the SINTEF Group, one of the largest independent research organisations in Northern Europe, and is a non-profit research organisation. The institute carries out R&D with the aim of promoting cost-effective and environmentally sound solutions for energy use and the supply of heat and power.

SINTEF-ER has a leading national position as an RTD provider within energy efficiency, energy processes, gas technology, thermo- and fluid dynamics, combustion and thermo-chemical conversion processes. The high-level technical profile developed by the institute, via activities such as assisting the Norwegian Parliament (Storting) to achieve its cross-party Climate Change Policy Consensus, means that its research community is now at the forefront of European energy research.

About HM Hospitales

The HM Hospitales Research Foundation is a non-profit body which was constituted in 2003 with the key goal of leading teaching in biomedical R&D&I within the framework of translational research, directly benefiting the patient and society in general both with regard to treatment of diseases and with regard to healthcare, the aim being to make Personalised Medicine a reality.

From the start, the HM Hospitales Research Foundation promoted, financed and led research projects in which doctors and researchers (basic and clinical) tried to resolve everyday healthcare problems with a direct benefit to patients, promoting medicine based on personalised scientific evidence.

The main sources of funding for the research projects come from private and public competitive grants, own funds, donations and collaborations with private citizens, companies and non-profit associations which promote and help to fund specific socio-healthcare and R&D&I projects.

In 2009, the HM Hospitales Research Foundation, in collaboration with CEU San Pablo University, launched a new formula for the management and promotion of translational R&D, driving the creation of privately-funded chairs. These chairs have been focused on implantology, robotic surgery, therapeutic targets, biomaterials and geriatric care, among other areas.

Finally, the HM Hospitales Research Foundation organises and promotes scientific dissemination and healthcare education activities with a clear focus on the training of healthcare professionals and the health education of the general public.

About Taronis Technologies, Inc.

Taronis Technologies, Inc. (TRNX) owns a patented plasma arc technology that enables two primary end use applications for fuel generation and water decontamination.

The Company’s fuel technology enables a wide use of hydrocarbon feedstocks to be readily converted to fossil fuel substitutes. The Company is developing a wide range of end market uses for these fuels, including replacement products for propane, compressed natural gas and liquid natural gas. The Company currently markets a proprietary metal cutting fuel that is highly competitive with acetylene. The Company distributes its proprietary metal cutting fuel through Independent Distributors in the U.S and through its wholly owned distributors doing business as “MagneGas Welding Supply”. The Company operates 22 locations across California, Texas, Louisiana, and Florida.

The Company’s technology can also be implemented for the decontamination of waste water, including sterilizing water, eradicating all pathogens. The technology is being tested to determine if it can completely eliminate pharmaceutical contaminants such as antibiotics, hormones and other soluble drugs suspended in contaminated water. Lastly, the technology process is capable of reducing or eliminating other contaminants, such as harmful metals, as well as nitrogen, phosphorus, and potassium levels that trigger toxic algae blooms. The technology has prospective commercial applications in the agricultural, pharmaceutical, and municipal waste markets. For more information on Taronis, please visit the Company’s website at http://www.TaronisTech.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events, including our ability to raise capital, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

For a discussion of these risks and uncertainties, please see our filings with the Securities and Exchange Commission. Our public filings with the SEC are available from commercial document retrieval services and at the website maintained by the SEC at http://www.sec.gov.

Investor Contacts:

Tyler Wilson
IR@TaronisTech.com

SOURCE: Taronis Technologies, Inc.

ReleaseID: 546911

Connecting technique and intelligence accelerates clinical competency

LIVINGSTON, NJ / ACCESSWIRE / May 30, 2019 / Milestone Scientific Inc. (NYSE: MLSS) today announced that its new CompuFlo® Epidural Trainer (CompuFlo Trainer), an instructional instrument that uses pressure sensing technology to improve confidence and success in epidural placements, is making its debut to thousands of anesthesia professionals at this week’s Euroanethesia 2019 Congress. Milestone Scientific is entering the medical education market with a full suite of learning tools to improve epidural placement by trainees:

CompuFlo Trainer & Disposables – A digital console built on Milestone Scientific’s patented Dynamic Pressure Sensing® platform with touch-screen monitor and internal pressure transducer. A multi-use, non-sterile disposable kit designed for 100 training procedures.
Skill Lab – 24/7 online access to instrument instruction, clinical literature and resources. Trainees can self-study in advance of CompuFlo Trainer use or refresh at any time.
Procedure Log – Subscription to a mobile-responsive tool that captures the results of epidural procedures. Ideal for lab groups to review performance and monitor skill development.

A Leap Forward in Anesthesia Training

Traditional loss-of-resistance technique relies on subjective factors to identify entry to the epidural space, which make insertion a difficult procedure to master for trainees. Studies show up to 90 patient epidural placements may be necessary to reach basic clinical competency.1

The CompuFlo Trainer links trainee tactile feel with visual and audible confirmation of pressure changes to verify the epidural space. CompuFlo’s real-time Dynamic Pressure Sensing technology® detects tissue changes that are imperceptible by touch. This intelligence allows the trainee to objectively discriminate between true and false loss of resistance and confirm location.

Instruction becomes more efficient as instructors, who previously depended solely on trainee feedback of their tactile feel, have visual and audible feedback of trainee needle movement during a procedure. Documentation is also generated for each procedure for review and trainee performance monitoring.

“Medical residency programs and simulation labs now have a complete training solution available to accelerate the procedure’s learning curve by reducing stress, uncertainty and the number of attempts to locate the epidural space,” comments Sharon Smith, Executive Vice President of Global Sales and Marketing of Milestone Scientific. “This digital educational suite enhances teaching and learning by building confidence through intelligence not previously available to instructors and trainees.”

CompuFlo Trainer explainer video highlights trainee needs: https://youtu.be/7EJCa1OAjgk

The CompuFlo Epidural Trainer is not intended for human use. Milestone Scientific previously announced an agreement with American 3B Scientific, a leading supplier of didactic material for medical education, to distribute the CompuFlo Trainer in North America, Central America and select countries in South America.

1 D. J. Kopacz, J. M. Neal, and J. E. Pollock, “The regional anesthesia ‘learning curve.’ What is the minimum number of epidural and spinal blocks to reach consistency?” Regional Anesthesia, vol. 21, no. 3, pp. 182–190, 1996.

About Euroanaesthesia 2019

Held June 1 – 3 in Vienna, Austria, Euroanaesthesia is Europe’s largest annual event showcasing the latest news and innovations with medical experts active in the field of anesthesia, perioperative medicine, intensive care, emergency medicine and pain treatment. This international event gathers upwards of six thousand delegates from around the world.

About Milestone Scientific Inc

Milestone Scientific Inc. (MLSS) is a medical device company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone’s computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone’s proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website: www.milestonescientific.com.

Contact:

David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone’s ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone’s control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone’s periodic filings with the Securities and Exchange Commission, including without limitation, Milestone’s Annual Report for the year ended December 31, 2018. The forward looking statements in this press release are based upon management’s reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

SOURCE: Milestone Scientific, Inc.

ReleaseID: 547116